Literature DB >> 12628101

[Cerebrovascular stroke as a sign of atrial myxoma in childhood].

L Ruiz Pérez1, A Sempere Pérez, A García Alonso, C Alenda González, J Flores Serrano.   

Abstract

Primary cardiac tumors are uncommon with an estimated incidence of between 0.0017 % and 0.19 %. Most are benign. Whereas myxomas are the most common primary tumor in adults, in children they are exceptionally rare. Cardiac myxomas usually develop in the left atrium, 20 % occur in the right atrium and the remainder develops in the ventricles and rarely in the heart valves. Cerebrovascular strokes secondary to myxoma are rare in childhood. The diagnostic test of choice is transesophageal echocardiogram and early excision is the most effective treatment in preventing serious complications. We report a case of cerebral stroke as the only manifestation of an atrial myxoma in an 11-year-old-girl. The patient presented vertigo, right hemiparesis of the body and dysarthria without loss of consciousness. After diagnostic tests (computerized tomography, magnetic resonance imaging and cerebral angioresonance) she was diagnosed with an ischemic lesion in the left middle cerebral artery. Various investigations were performed to find the cause of the stroke, among them cardiologic study, and a mass in the left atrium suggestive of myxoma was found. The tumor was removed and the diagnosis of myxoma was confirmed by histopathological examination. Outcome was satisfactory. The presence of a cerebral ischemic episode, with or without concomitant heart disease, suggests the need to look for cardiac etiology.

Entities:  

Mesh:

Year:  2003        PMID: 12628101     DOI: 10.1016/s1695-4033(03)78050-3

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  1 in total

1.  Carney complex presenting with Raynaud's phenomenon and erythematous macules of the extremities.

Authors:  L J Mirkinson; K Ratnayaka; C A Sable; P R A Gaskin
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.